Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made on the effectiveness of nintendanib for patients suffering from pulmonary fibrosis.

Nintedanib is routinely available to eligible National Health Service patients according to the National Institute for Health and Care Excellence’s (NICE) guidance, which recommends nintendanib for treating idiopathic pulmonary fibrosis for patients with a Forced Vital Capacity of between 50 to 80% predicted.

NICE is currently reviewing its recommendations on the use of nintedanib for the treatment of idiopathic pulmonary fibrosis in those with a forced vital capacity above 80% predicted and currently expects to publish final guidance in March 2023.